{"schema_version":"secwatch.filing_event.v1","accession":"0000939767-23-000078","form_type":"8-K","ticker":"EXEL","cik":"0000939767","company_name":"EXELIXIS, INC.","filed_at":"2023-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.095266+00:00","generated_at":"2026-06-12T21:35:38.945181+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Exelixis Q2 revenue $469.8M, GAAP EPS $0.25; CABOMETYX drives growth","bullets":["Total revenues $469.8M (+12% YoY); net product revenues $409.6M (+18% YoY).","GAAP diluted EPS $0.25; non-GAAP diluted EPS $0.31, vs $0.22 and $0.28 last year.","CABOMETYX remains top TKI in RCC; growth driven by first-line combo with nivolumab.","Pipeline advances: zanzalintinib STELLAR-001 enrollment complete; XB002 dose selected.","Upcoming catalysts: CONTACT-02 readout, COSMIC-313 OS analysis, R&D Day Dec 12."],"urls":{"canonical":"https://secwatch.observer/filing/0000939767-23-000078","json":"https://secwatch.observer/filing/0000939767-23-000078.json","markdown":"https://secwatch.observer/filing/0000939767-23-000078.md","text":"https://secwatch.observer/filing/0000939767-23-000078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/939767/000093976723000078/0000939767-23-000078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/939767/000093976723000078/exel-20230801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T21:35:38.945181+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3bcf96daa0af72b767592da379b28df89d4786fe","claim":"EXELIXIS, INC. reported the quarter ended June 30, 2023 results: revenue Total revenues of $469.8 million, net income GAAP net income of $81.2 million, or $0.25 per share, EPS $0.25 per share.","evidence_excerpt":"Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update - Total Revenues of $469.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $409.6 million - - GAAP Diluted EPS of $0.25, Non-GAAP Diluted EPS of $0.31","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/939767/000093976723000078/0000939767-23-000078-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"Total revenues of $469.8 million"},{"label":"Net income","value":"GAAP net income of $81.2 million, or $0.25 per share"},{"label":"EPS","value":"$0.25 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}